BreakSight, Inc.

BreakSight, Inc.

生物技术研究

Allentown，PA 181 位关注者

Advancing precision medicine by uncovering site-specific DNA breaks and enabling discovery of DNA biomarkers of response

关注

关于我们

Characterizing and treating cancers with an evolving and dynamic genome remains a challenge. BreakSight’s vision is to help address this challenge and advance precision medicine by enabling the discovery of novel DNA sequence biomarkers of response to targeted cancer therapeutics and compounds. With one of the first commercial assays to identify DNA sequences associated with frequent DNA damage, our streamlined services can unveil site-specific maps of DNA breakage and reveal DNA-damaging mechanisms of cancer therapeutics with high resolution and specificity. DNA break signatures identified by our technology offer a greater understanding of DNA-damaging drugs, such as DDR inhibitors, the pathways that they target, and mechanisms of genomic instability previously left unchartered. Find out how your drug affects the genome and discover potentially new DNA biomarkers of drug response and efficacy. Our products: DDsite – - Performance of our BrITL assay to tag and retrieve DNA double-strand break sites across the genome from cells exposed to treatment(s) that induces DNA damage during proliferation - Performance of next-generation sequencing on captured DNA break fragments DDinsight – - Analysis of sequence data through our stringent analysis pipeline to pinpoint reproducible sites of breakage across the genome - Uncover DNA repeats and sequence motifs that are enriched across identified DNA break sites - Compare sites across conditions Further customized analysis can be performed upon request - please reach out!

网站
https://www.breaksight.net/
所属行业
生物技术研究
规模
2-10 人
总部
Allentown，PA
类型
私人持股

产品

点击此处查看DDsite

点击此处查看DDsite DDsite

Our unique platform tags, retrieves, and localizes DNA double-stranded breaks in cells exposed to acute DNA damage-inducing treatments with site-specific precision. Performance of next-generation sequencing reveals regions of DNA damage genome-wide, laying the foundation for mechanistic insights into the drug’s effect on the cancer genome. In addition, DDinsight provides bioinformatics services, which probes sequenced data through our analysis pipeline to pinpoint reproducible sites of DNA breakage across the genome, specific to customer treatment conditions. With analysis from multiple samples, our report can also include comparison of break sites across different treatments. Upon request, DDinsight+ further uncovers DNA repeats and sequence motifs enriched at identified break sites and conducts overlap analysis with publicly available databases of genome-wide elements (e.g. ChIP-Seq data, gene regions, histone marks, etc.), offering a deeper understanding of DNA break patterns.

地点

  • 主要

    7540 Windsor Drive

    Suite 210

    US，PA，Allentown，18106

    获取路线

BreakSight, Inc.员工

查看全部员工

动态

相似主页